123I-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21 WAF-1/Cip-1

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 3, 2007, Pages 368-377

  Hu, Meiduo ^a,c   Chen, Paul ^a   Wang, Judy ^a   Scollard, Deborah A ^a   Vallis, Katherine A ^a,b   Reilly, Raymond M ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Breast cancer; HIV 1 tat peptides; Intracellular epitopes; Nuclear localization; p21WAF 1 Cip 1; Radioimmunoconjugates

Indexed keywords

ANTIBODY CONJUGATE; BETA ACTIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1 ANTIBODY GLYCYLARGINYLLYSYLLYSYLARGINYLARGINYLGLUTAMINYLARGINYLARGINYLARGINYLPROLYL PROLYLGLUTAMINYLGLYCYLTYROSYLGLYCYLCYSTEINE; CYCLIN DEPENDENT KINASE INHIBITOR 1 ANTIBODY GLYCYLARGINYLLYSYLLYSYLARGINYLARGINYLGLUTAMINYLARGINYLARGINYLARGINYLPROLYL PROLYLGLUTAMINYLGLYCYLTYROSYLGLYCYLCYSTEINE I 123; CYCLIN DEPENDENT KINASE INHIBITOR 1 ANTIBODY I 123; EPIDERMAL GROWTH FACTOR; GLYCYLARGINYLLYSYLLYSYLARGINYLARGINYLGLUTAMINYLARGINYLARGINYLARGINYL PROLYLPROLYLGLUTAMINYLGLYCYLTYROSYLGLYCYLCYSTEINE I 123; IMMUNOGLOBULIN G ANTIBODY; RADIOPHARMACEUTICAL AGENT; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 1A; RADIOACTIVE IODINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL LYSATE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONJUGATE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG UPTAKE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PROTEIN DOMAIN; PROTEIN INDUCTION; RADIOACTIVITY; TUMOR XENOGRAFT; WESTERN BLOTTING; ACTIVE TRANSPORT; ANIMAL; ANTIBODY SPECIFICITY; BREAST TUMOR; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; NUDE MOUSE; PROTEIN BINDING; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE PRODUCTS, TAT; HUMANS; IODINE RADIOISOTOPES; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; ORGAN SPECIFICITY; PROTEIN BINDING; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 33847105943     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0189-0     Document Type: Article

References (31)

1. DeNardo SJ. Radioimmunodetection and therapy of breast cancer. Semin Nucl Med 2005;35:143-51.
2. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005;46:115S-127S.
3. Reilly RM. Biomolecules as targeting vehicles for in situ radiotherapy of malignancies. In: Knaeblein J, ed. Modern biopharmaceuticals: design, development and optimization., vol. 2. Weinheim, Germany: Wiley-VCH; 2005. pp. 497-526.
4. Misek DE, Imafuku Y, Hanash SM. Application of proteomic technologies to tumor analysis. Pharmacogenomics 2004;5:1129-37.
5. Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagener C, Kallinich B, et al. Expression of the Bcl-2 gene family in normal and malignant breast tissue: low bax-α expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 1995;60:854-9.
6. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4.
7. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000;60:6788-93.
8. Hu M, Chen P, Wang J, Chan C, Scollard DA, Reilly RM. Site-specific conjugation of HIV-1 tat peptides to IgG: a potential route to construct radioimmunoconjugates for targeting intracellular and nuclear epitopes in cancer. Eur J Nucl Med Mol Imag 2005;33:301-10.
9. cip1 and consequences of its mutation on cell proliferation. FEBS Lett 2002;531:319-23.
10. cip1 and is involved in the regulation of its nuclear localization. J Biol Chem 1999;274:24445-8.
11. 1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
12. Gorospe M, Wang X, Holbrook NJ. Functional role of p21 during the cellular response to stress. Gene Expr 1999;7:377-85.
13. Fang M, Liu B, Schmidt M, Lu Y, Mendelsohn J, Fan Z. Involvement of p21Waf1 in mediating inhibition of paclitaxel-induced apoptosis by epidermal growth factor in MDA-MB-468 human breast cancer cells. Anticancer Res 2000;20:103-11.
14. WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways. Int J Oncol 1998;12:793-804.
15. Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition. J Cell Biol 1995;131:235-42.
16. Armstrong DK, Kaufmann SH, Ottaviano YL, Furuya Y, Buckley JA, Isaacs JT, et al. Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. Cancer Res 1994;54:5280-3.
17. Thomas T, Balabhadrapathruni S, Gardner CR, Hong J, Faaland CA, Thomas TJ. Effects of epidermal growth factor on MDA-MB-468 breast cancer cells: alterations in polyamine biosynthesis and the expression of p21/CIP1/WAF1. J Cell Physiol 1999;179:257-66.
18. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 1994;91:648-64.
19. WAF-1/CIP-1 gene expression in MDA-MB-468 human breast cancer xenografts. Eur J Nucl Med Mol Imaging 2003;30:1273-80.
20. Vocero-Akbani AM, Heyden NV, Lissy NA, Ratner L, Dowdy SF. Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat Med 1999;5:29-33.
21. Kip1 induces cell migration. Nat Med 1998;4:1449-52.
22. Schwarze SR, Ho A, Vocero-Akbani AM, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999;285:1569-72.
23. Caron NJ, Torrente Y, Camirand G, Bujold M, Chapdelaine P, Leriche K, et al. Intracellular delivery of a Tat-eGFP fusion protein into muscle cells. Mol Ther 2001;3:310-8.
24. Zhao M, Kirscher MF, Josephson L, Weissleder R. Differential conjugation of tat peptide to supermagnetic nanoparticles and its effect on cellular uptake. Bioconjug Chem 2002;13:840-4.
25. 99mTc-antisense DNAs without entrapment. Mol Imaging Biol 2003;5:240-7.
26. Niesner U, Halin C, Lozzi L, Günthert M, Neri P, Wunderli-Allenspach H, et al. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug Chem 2002;13:729-36.
27. Reilly R. The immunoreactivity of radiolabeled antibodies - its impact on tumor targeting and strategies for preservation. Cancer Biother Radiopharm 2005;19:669-72.
28. Leonard JL, Rennke H, Kaplan M, Larsen PR. Subcellular distribution of iodothyronine 5′-deiodinase in cerebral cortex from hypothyroid rats. Biochim Biophys Acta 1982;718:109-19.
29. 131I] SIPMB, a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs. Bioconjug Chem 2003;14:331-41.
30. Sheshberadaran H, Payne LG. Protein antigen-monoclonal antibody contact sites investigated by limited proteolysis of monoclonal antibody-bound antigen: protein "footprinting". Proc Natl Acad Sci USA 1988;85:1-5.
31. Reilly RM, Sandhu J, Alvarez-Diez T, Gallinger S, Kirsh J, Stern HS. Problems of delivery of monoclonal antibodies-Pharmacokinetic and pharmaceutical solutions. Clin Pharmacokin 1995;28:126-42.